Latest Dana-Farber Cancer Institute Stories
Scientists at Dana-Farber Cancer Institute have discovered a molecular switch that enables advanced prostate cancers to spread without stimulation by male hormones, which normally are needed to spur the cancer's growth.
An experimental drug combination for preventing graft-versus-host disease (GVHD) was not significantly better than the standard regimen on key endpoints.
Young patients with an aggressive form of leukemia who are likely to relapse after chemotherapy treatment can significantly reduce those odds by receiving additional courses of chemotherapy.
A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies.
Terminally ill cancer patients who have an early talk with their physician about care at the end-of-life are less likely to receive aggressive therapy – and more likely to enter hospice care – than patients who delay such discussions until the days and weeks before death.
Findings from a nationwide study led by researchers at Dana-Farber Cancer Institute suggest that patients with advanced lung or colorectal cancer are frequently mistaken in their beliefs that chemotherapy can cure their disease.
- A serpent whose bite was fabled to produce intense thirst.